Description
Badges:
- HPLC/MS Verified
- QR-linked COA per batch
- Secure Payments (Card + Crypto)
- Fast Canada Shipping
🔬 Science & Mechanism
PT-141 is a melanocortin receptor agonist derived from melanotan II.
- Acts on MC3R/MC4R receptors in the brain’s sexual motivation centers.
- Increases dopamine activity, linked to libido and arousal.
- Different from Viagra/Cialis → works centrally on desire, not just vascularly.
📊 Clinical Evidence
- FDA-approved in 2019 (Vyleesi) for female sexual dysfunction (HSDD).
- Clinical trials showed increased sexual desire and satisfaction in women.
- In men, PT-141 improved arousal, even in PDE5 “non-responders.”
💉 Dosing Guide (Educational)
Reported Protocols:
- Subcutaneous injection: 1–2 mg, as needed, ~30–60 minutes before intimacy.
- Start with 0.5–1 mg to assess tolerance.
- Effects may last up to 24–36 hours.
💧 Reconstitution (10 mg vial + 2 mL BAC water)
- Final concentration = 5 mg/mL
- On insulin syringe (100 units = 1 mL): 50 mcg per unit
| Desired Dose |
Volume (mL) |
Syringe Units |
| 0.5 mg |
0.10 mL |
10 units |
| 1.0 mg |
0.20 mL |
20 units |
| 1.5 mg |
0.30 mL |
30 units |
| 2.0 mg |
0.40 mL |
40 units |
🧊 Storage
- Refrigerate lyophilized vial (2–8 °C).
- After reconstitution, refrigerate and use within 30 days.
- Protect from light.
❓ FAQ
How is PT-141 different from Viagra or Cialis?
Viagra improves blood flow; PT-141 activates brain pathways linked to arousal and desire.
Can women use PT-141?
Yes — PT-141 is FDA-approved (Vyleesi) for female sexual dysfunction.
Does it stack with other intimacy peptides?
Yes — stack with Kisspeptin-10 for hormonal arousal, or Oxytocin for bonding and connection.
⚠️ Disclaimer
- For educational purposes only.
- Not FDA or Health Canada approved outside specific indications.
- Customers assume responsibility for safe handling.
📚 References
- Kingsberg SA, et al. Bremelanotide for female hypoactive sexual desire disorder: phase 3 RECONNECT trials. J Sex Med. 2019.
🔗 https://pubmed.ncbi.nlm.nih.gov/31351961/
- FDA Approval: Vyleesi (Bremelanotide) for HSDD. 2019.
🔗 https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-low-sexual-desire-women
- Wessells H, et al. Bremelanotide for male erectile dysfunction: clinical evidence. Urology. 2000.
🔗 https://pubmed.ncbi.nlm.nih.gov/10840092/
Reviews
There are no reviews yet.